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Clinical Symptoms of Adult Metachromatic 
Leukodystrophy and Arylsulfatase A 
Pseudodeficiency
A. T. M. Haganan, MD; F. J. M. Gabreëls, MD; J. G, N. de Jong, MD; A. A. W. M. Gabreèls-Festen, MD; 
C. J. M, G. van den Berg, MD; B. A. van Oost, MD; R. A. Wevers, MD
Objective: To determine the clinical symptoms in adult
ficiency for arylsulfatase A.
Design: Case series.
Setting: University hospital.
Patients: Twenty-five adult patients with very low ar­
ylsulfatase A activity.
Results: In 13 patients, a diagnosis of adult metachro­
matic leukodystrophy was made. The main symptoms 
were dementia, behavioral abnormalities, ataxia, and
polyneuropathy. In 12 patients, a diagnosis of arylsul­
fatase A pseudodeficiency was made. No character­
istic clinical syndrom e could  be detected in these 
patients,
Conclusions: Adult metachromatic leukodystrophy is 
a progressive metabolic disease with symptoms of de- 
myelination of the central and peripheral nervous sys­
tems. Diagnosis must be confirmed by determination of 
arylsulfatase A activity and accumulation of sulfatides. 
Pseudodeficiency for arylsulfatase A can be confirmed or 
excluded by means of DNA analysis.
(Arch N eurol 1995;52:408-413)
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ETA c h r o m a t ic  leuko­
dystrophy (MLD) is an 
autosomal recessive ly­
sosomal disorder char­
acterized by demyelin- 
ation of the white matter in the central 
nervous system and the peripheral nerves. 
The gene is located on chrom osom e 
22q l3 . 1 Accumulation of sulfatides can be 
found in the brain, peripheral nerves, and 
nonneural organs. The disease is caused 
by a deficiency of the enzyme arylsulfa­
tase A (ASA), which hydrolyzes various 
sulfatides, including galactosyl sulfatide 
and lactosyl sulfatide, the major sulfate- 
containing lipids of the nervous system. 
The diagnosis of MLD is based on de­
creased ASA activity in leukocytes or fi­
broblasts and accumulation of sulfatides 
in urinary sediment or various tissues, eg, 
sural nerve.
Clinically different forms of MLD can 
be distinguished according to the severity 
and the age at onset of the disease. The late- 
infantile form (age at onset, 1 to 2  years) is 
characterized by gait and behavioral distur­
bances; the disease course is rapid and the 
outcome is fatal.2 The juvenile form of MLD 
(age at onset, 3 to 15 years) has a more pro­
tracted course.3 The adult form of MLD (age
at onset older than 16 years) has a slowly 
progressive course. Compared with the late- 
infantile and juvenile forms of MLD, the 
adult variant appears to be quite rare. Un­
til now, to our knowledge, only 24 pa­
tients w ith  adu lt MLD have been de­
scribed in the literature. In these patients, 
a low ASA level was accompanied by accu­
mulation of sulfatides.4' 6
The determination of ASA deficiency 
alone is insufficient for a diagnosis of MLD, 
because a pseudodeficiency (PD) state has 
also been observed .7 In the PD state, low 
ASA activity is not accompanied by accu­
mulation of sulfatides in the organs, be­
cause the residual activity is supposedly suf- 
f ic ie n t  to e n s u re  n o rm a l su lfa tid e  
metabolism. This PD state is a common ge­
netic polymorphism, with an estimated gene 
frequency of 7.3% in central Europe,H and 
is caused by a mutation affecting the poly- 
adenylation of the ASA mRNA.7
Until now, eight different MLD alle­
les have been described .0 The three dif-
See Patients and M ethods 
on n ex t page
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PATIENTS AND METHODS
During the period from 1972 to 1992,25 patients aged 
older than 16 years were found to have very low ASA 
activity in the leukocytes, ranging from I. to 25 nmol/h 
per milligram of protein (reference range, 35 to 110 
nm o I/li per milligram of protein).
PATIENTS W ITH  MLD
The diagnosis of MLD was confirmed in 13 patients 
by morphologic demonstration of storage material 
in the sural nerve or brain an cl/or increased amounts 
of sulfa tides in urinary sediment (Table 1 ). Two pa­
tients (patients 2 and 3) have been described previ­
ously. 10 In patient 3, ASA activity was not determined, 
but we can be sure of the diagnosis because he was 
the brother of patient 2 ; they presented with similar 
clinical features, and a postmortem ncuropathologic 
examination revealed accumulation of sulfatides in 
the brains of both patients. A survey of technical mea­
surements performed in the patients with adult MLD 
is presented in Table 1. Electromyography (EMG) was 
performed in 1 1  patients, and analysis of cerebrospi­
nal fluid was performed in 1 0  patients, Neither com­
puted tomography (CT) nor magnetic resonance im­
aging (MRI) was available during the lifetime of pa­
tients 1 through 4. Peripheral nerve biopsy specimens 
from four patients (patients 2,4, 5, and 6 ) were stud­
ied in our department, and the morphologic changes 
were compared with the features in late-infantile and 
juvenile cases. Pathologic examination of the sural 
nerve of patients 9,12, and 13 was performed in other 
hospitals.
PATIENTS W ITH  PD
Twelve patients with low ASA activity were found to 
be homozygotic for the PD mutation. Lysosomal en­
zyme determination in these patients was requested 
based on progressive neurologic or psychiatric signs 
and symptoms of unknown etiology. Examination 
of the sural nerve was performed in two patients. In 
the other 1 0  patients, biopsy was not performed be­
cause they showed no neurophysio logic or radiologic 
symptoms o fie ukodys trophy, and DN A analysis for 
PD became available. In all patients, DNA analysis 
was perfonned. In three pa tien is, ti n na Iysis was per­
ror med, Ten patients underwent EMG, nine under­
went CT, and three underwent MRI. The cerebrospi­
nal fluid from five patients was analyzed.
Arylsulfatase A activity was measured in leukocyte 
supernatants after sonification with use of p-nitro- 
catecholsulfate as substrate, as described by Galjnard,11 
Urinary sulfatides were extracted from sedimen is, sepa­
rated by thin-layer chromatography from other glyco- 
lipids, and estimated semiquantitatively after naphlhol 
staining, Leukocyte genomic DNA was initially typed 
for the PD allele by the method of Gieselmann12 and later 
by the method of Nelson et al.n
ity for type 0  alleles is associated with the late-infantile 
form. Homozygosity for the type R alleles is present in 
adult forms, while type O/type R compound heterozy­
gotes have intermediate (juvenile) phenotypes.^
Herein, we describe 25 adult patients with low ASA 
activity. In 13 patients, the diagnosis of adult MLD was 
confirmed by demonstration of sulfatide accumulation. 
In 1 2  patients, no accumulation could be demonstrated. 
In the latter group, a diagnosis of PD was established by 
means of DNA analysis. The data from both groups are 
compared with data from the literature.
R L S U I I S
ferent forms of the disease can be explained by the ex­
istence of two types of alleles; type 0  alleles without and 
type R alleles with some residual activity, Homozygos­
The range of ASA activity in the leukocytes of the 13 pa­
tients with adult MLD was 1 to 12 nmol/h per milligram 
of protein (reference range, 35 to 110 nmol/h per milli­
gram of protein) (Figure 1 ). The mean age at onset in the 
adult MLD group was 23 years (range, 16 to 31 years). The 
presenting clinical symptoms were behaviohil abnormali­
ties (n=4 ), ataxia (n=4 ), polyneuropathy (ii=2 ), dementia 
(n=:2 ), and paraparesis (n=l) ( T a b le  2 ), The behavioral 
abnormalities consisted of aggressiveness, irritability, im­
paired social awareness, and inappropriate behavior, The 
interval between age at onset and age of occurrence of the 
second symptom was, on average, 3.7 years (range, 1 to 
20 years). The third symptom occurred, on average, 2.0 
years (range, 0 to 7 years) after the second symptom. The 
development of the main symptoms is graphically pre­
sented in Figure %, In the final stage of the disease, most 
of the patients were suffering from mental deterioration 
(n=1 0 ) and showed severe ataxia (n=8 ) and behavioral ab­
normalities (n=6 ). Three patients developed epilepsy. None 
of the patients became psychotic, except for patient 3, who 
suffered from auditory hallucinations, Plantar response was 
flexor in six patients and extensor in seven patients. In three 
patients, paraparesis was evident
All of the patients with MLD who underwent EMG 
showed a slowing of the nerve conduction velocities (NCVs) 
(Table 1). The mean NCV of the peroneal nerve was 24.4 
m/s (range, 15 to 39 m/s; reference range, 4-4 to 57 m/s).
Neuropat ho logic examination of the sural nerve in 
three patients (patients 2 ,4 , and 5) revealed, with acidic 
cresyl violet staining, the presence of brown metachro­
matic deposits in Schwann cells and in large perivascu­
lar macrophages, A process oTsegmental dcmyelination 
and remyelination with slight onion bulb formation was 
present, but this was less active than in the late-infantile 
and juvenile forms, and myelinated fiber density was only 
slightly reduced, in contrast to the more pronounced re­
duction in the earlier-onset cases, Myelin sheath thick­
ness was clearly reduced, especially that of the large fi­
bers. In patien t 6 , the m yelinated fiber density, the 
percentage of large fibers, and the myelin thickness were 
normal. There were few signs of segmental dcmycUn- 
ation and remyelination, but accumulation of metachro­
matic material was in the same range as in most adult 
and juvenile cases. Ultras truetural examination in all four 
patients revealed various types of inclusions, mainly la­
mellar zebralike bodies and tuffstone bodies. The speci­
mens from the three patients whose biopsies were per­
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Table 1. Technical Measurements in 13 Patients With Adult Metachromatic Leukodystrophy *
Patient
Variable
I '
1 2 3 4 5 6 7 8
Sex F M M F F F M M
Age at onset, y
ASA activity, 
nmol/h per mg of protein
30 27 26 29 21 16 18 20
Leukocytes 
(reference range, 
35-110)
2 4 ND 1 3 4 10 3
Fibroblasts 
(reference range, 
270-770)
MD ND ND 11 75 25 ND 19
Accumulation of sulfatides Brain Brain, sural 
nerve
Brain Sural nerve Sural nerve Sural nerve Urine Urine
CT findings ND ND ND ND Hypodensities Hypodensities Hypodensities Hypodensities
MRI findings ND ND ND ND ND ND ND ND
CSF protein, g/L 
(reference range, 0.18-0.58 g/L)
ND 0.38 0.34 ND 0.50 0.26 0.50 ND
NCV of peroneal nerve, m/s ND 15 ND 30 24 39 24 27
(reference range, 44-57 m/s)
*ASA indicates arylsulfatase A; ND, not done; CT, computed tomographic; MR I, magnetic resonance imaging; CSF, cerebrospinal fluid; and NC Vt nerve 
conduction velocity.
formed in other hospitals were not available for review, 
but accumulation of m etachrom atic material was re­
ported in all of them.
Computed tomography was performed in nine pa­
tients and revealed areas of hypo density in the white mat­
ter, especially in the frontal lobes. Magnetic resonance 
imaging was performed in  three patients and showed dif­
fuse demyelination of the periventricular white matter
(Figure 3).
Analysis of cerebrospinal fluid from 10 patients re­
vealed normal (n=7) or slightly elevated (n=3) protein 
levels (range, 0.26 to 0.73 g/L) (reference range, 0.18 to
0.58 g/L).
At the time of this writing, nine of these patients have 
died. On average, death occurred 9.8 years (range, 3 to 
24 years) after onset of the disease. Four patients are still 
alive an average of 16 years (range, 1 1  to 27 years) after 
disease onset.
In the 12 other patients with very low ASA activity, 
DNA analysis revealed homozygosity for the PD allele. The 
ASA activity in this group ranged from 6  to 25 nmol/h per 
milligram of protein. The levels of ASA activity for both 
groups are presented in Figure 1. The complaints of these 
patients were memory disturbances (n=6 ), ataxia (n=2 ), 
fatigue (n~2), tremor (n=l), and loss of vision (n=l). These 
patients were not related to patients known to have MLD. 
One patient was found to have multiple sclerosis, one was 
found to have Parkinson’s disease, one was found to have 
Huntington’s disease, and one was found to have an is­
chemic optic neuropathy. Neurologic and neuropsycho­
logical examinations of the six patients with memory com­
plaints revealed no abnormalities, In addition, EMG, CT, 
and MRI yielded normal findings, while no evident ab­
normalities were found in  the cerebrospinal fluid, with the 
exception of an elevated IgG index and oligoclonal bands 
in the patient with multiple sclerosis. Analysis of the urine 
revealed no evidence of accumulation of sulfa tides. A su­
ral nerve biopsy was performed in two patients with PD.
In one, no abnormalities were found. In the second, acidic 
cresyl violet staining revealed a few deposits of brown meta­
chromatic material perinuclearly in Schwann cells in ad­
dition to signs of chronic axonal degeneration and regen­
eration. The ASA activity in this patient was 10 nmol/h 
per milligram of protein.
C O M M E N T
We describe the signs and symptoms of 13 patients with 
adult MLD who demonstrated low ASA activity and ac­
cumulation of sulfatides and of 12 patients with PD. Un­
til now, only 25 patients with confirmed adult MLD have 
been described in the literature. In 1991, the clinical signs 
and symptoms of 23 patients with MLD described in the 
literature were reviewed by Baumann et nl.4 One patient 
from their review was not included in our analysis be­
cause he was already included as patient 2  in the pres­
ent study. Recently, two other patients with confirmed 
MLD have been described . '5,11 Table 2 summarizes the pre­
senting symptoms of our patients with adult MLD and 
the symptoms of the disease in the developed state; it also 
outlines the clinical symptoms of the patients described 
in the literature. The mean age at onset in our patients 
was 23 years (range, 17 to 31 years), comparable with 
that reported in the literature (mean age at onset, 24 years; 
range, 16 to 62 years). Most of the patients described were 
younger than age 40 years at onset, wi th one exception, 
an elderly patient with an age at onset of 62 years . 14
The m ost com m on p resen tin g  sym ptom s de­
scribed in the literature are mental deterioration and be­
havioral abnormalities (Table 2). In our group, the most 
common presenting symptoms were ataxia and behav­
ioral abnormalities, and only two of our patients pre­
sented with mental deterioration. In the early stages of 
the disease, the patients were not evaluated with neuro­
psychological testing, so we cannot rule out that the be­
havioral abnormalities represent early manifestations of
ARCH NEUROL/VOL 52, APR 1995
410
30
9 10 11 12
.................  I
13
F F M F F
19 17 31 20 23
3 4 3 12 7
16 ND 14 43 ND
Sura! nerve Urine Urine Surai nerve Sural nerve
Hypodensities Hypodensities Hypodensities Hypodensities Hypodensities
ND Demyelination Demyelination Demyelination ND
0.64 0.32 0.73 0.61 0.58
20 20 29 17 23
mental deterioration. Compared with late-infantile MLD, 
in  which the motor symptoms predominate in die early 
stage , 1 it seems that a combination of mental and behav­
ioral symptoms and ataxia predominate in die adult form 
of MLD.
The course of the disease is slowly progi'essive, and 
the variability in progression is remarkable. Sometimes 
the patients developed the second and third symptom 
within 1 year. On the other hand, in one patient, the sec­
ond symptom did not become evident for 2 0  years. In 
the developed state of the disease, most of the patients 
showed mental deterioration, and about half exhibited 
behavioral abnormalities and ataxia. Sometimes behav­
ioral abnormalities and dementia15 or polyneuropathy*1 
are the only symptoms for many years; this might be why 
adult MLD is probably underdiagnosed. As in  late- 
infantile and juvenile MLD, epilepsy tends to be a late 
feature . 2 Only one of the 13 patients became psychotic. 
On the other hand, in a review of the literature, Iiyde et 
a 11 suggested that in 53% of patients with adu 11 MLD, 
psychosis is present and often the initial manifestation. 
In. most of these patients, however, only ASA activity was 
determined, while sulfatide accumulation was not dem­
onstrated, and DNA analysis to exclude PD was not per­
formed. Of the group of 24 patients with confirmed MLD 
in the literature, only four were psychotic . 1,1 M'f Appar­
ently, psychosis is a less common symptom than for­
merly suggested.
The course of adult MLD is not as rapidly fatal as 
the. late-infantile and juvenile forms of MLD. Although 
some of our patients are still alive, we have calculated 
the mean survival to be at least 1 2  years, which is longer 
than the survival in late-infantile MLD (3 to 4 years’) and 
juvenile MLD (7 to 9 years);,u
In all the patients who underwent cerebral CT, bi- 
la ter a 1 a re as o f hyp o d e ns i Ly w e r e fo u n d i n Lh e wh i t e m a 1 - 
ter, especially in the frontal lobes. In addition to the ar­
eas ofhypodensity, cerebral atrophy can be seen as a result
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Figure 1. Arylsulfatase A (ASA) activity in the leukocytes o f patients with 
adult metachroma tic leukodystrophy (MLD) and ASA pseudodeficiency 
(PD) (reference range, 35 to 110 nmol/h per milligram o f protein).
of the loss of m yelin . 20 In die three patients who under­
went MRl of the brain, the areas ofhypodensity were more 
diffuse and pronounced than on CT scans (Figure 3). 
Analysis of the cerebrospinal fluid revealed normal pro­
tein levels in seven patients and only slightly elevated pro­
tein levels in three patients, which is in contrast with late- 
infantile and juvenile MLD, in which the CSF protein level 
is usually more markedly elevated (0,44 to 2.25 g/L),*^
Polyneuropathy is seldom the first clinical symp­
tom (Table 2). Only two of our 13 patients showed overt 
clinical sym p to ms o f p o 1 y n eu r o p a thy. Th c N C Vs, o n I h c 
other hand, were markedly slowed in all of our patients, 
suggesting a demyelinatingprocess. In the literature, only 
one patient with adult MLD with normal NCVs has been
~l The decreased NCVs in the peroneal nerve 
(mean, 24.4 m/s; range, 15 to 39 m/s) is noL so marked 
as in late-infantile MLD (range 0 to 30 m/s) or in juve­
nile MLD (range, 10 to 28 m/s)."
In adult MLD, the process of segmental demyelin­
ation in the peripheral nerves is less active than in the 
juvenile and especially the late-infantile forms, The 
amount of metachromatic deposits does not differ clearly 
from that of the juvenile form. The moderate to marked 
slowing of NCVs in adult MLD is in accordance with the 
pathologic changes in the nerve biopsy specimen indi­
cating demyelination and reduction  of myelin sheath
f > c  / '; V»
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Table 2. Clinical Symptoms in Adult Metadiromatlc Leukodystrophy
At Presentation Developed
1 ----------
Patients Literature Total (%)
I
Patients Literature Total (%)'
M 3 ) (n=24*) (N—37) M 3 ) (n=24*) (N= 37)
Dementia 2 13 15(40.5) 10 21 31 (83.8)
Behavioral abnormalities 4 8 12(32.4) 6 8 14 (37.8)
Ataxia 4 4 8(21.6) . 8 12 20 (54.1)
Paraparesis 1 3 4(10.8) 3 9 12 (32,4)
Polyneuropathy 2 2 4(10.8) 2 2 4 (10.8)
Epilepsy 0 1 1 (2.7) 3 6 9 (24.3)
Psychosis 0 0 0(0) 1 4 5 (13,5)
* Patients from the literature include those described by Baumann et al,4 Sad eh et al,s and Fressinaud et ai:
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Figure 2. Development o f clinical symptoms in 13 patients with aduit 
metachromatic leukodystrophy.
thickness,22' 25 In one patient (patient 6 ) who showed the 
best-preserved NCVs in our series of patients with adult 
MLD, accumulation of sulfaticles could be seen on light 
and electron microscopic examination, but signs of a de­
myelinating process were minimal, no substantial fiber 
loss had occurred, and sheath thickness was normal. Com­
parable findings were reported by Martin et al2fi in a pa­
tient with adult MLD with moderate slowing of NCVs 
whose nerve biopsy specimen revealed mild demyelin­
ation and normal sheath thickness. On the other hand, 
Fressinaud et al,{1 in their report of a patient with adult 
MLD with an isolated neuropathy, noted marked slow­
ing of NCVs and conduction blocks, as well as wide­
spread demyelinating lesions in the nerve biopsy speci­
mens. There are apparently marked differences in the 
severity of the neuropathy within the group of patients 
with adult MLD. This is also reflected by the electro- 
physiologic and morphologic features. No correlation 
exists between the NCV and the am oun t of storage 
material in the peripheral nerve.
Treatment of late-infantile MLD with bone mar­
row transplantation has produced conflicting results , 1 but 
incidental success has been claimed in a few patients 
whose motor and cognitive development were almost nor­
mal during several years after bone marrow transplan-
Figure 3. Magnetic resonance image o f a patient with adult MLD, showing 
diffuse demyelination o f the white matter.
tation,27,2H As far as we know, bone marrow transplanta­
tion has not been reported in cases of adult MLD.
In the 12 patients with PD, no characteristic clini­
cal syndrome could be detected. An association with mul­
tiple sclerosis20 and dystonia30 has been suggested, but 
no causal relationship has been proved. Only one of our 
patients with PD turned out to have multiple sclerosis. 
The symptoms and signs of the other 11 patients re­
vealed no abnormalities as seen in MLD, suggesting that 
PD is not related to demyelination of the central or pe­
ripheral nervous systems. In the sural nerve of one pa­
tient, small amounts of metachromatic material were 
found. Chronic axonal degeneration of undetermined 
cause may have induced a slight accumulation of sulfa- 
tides owing to an increased turnover of myelin and low 
ASA activity (10 nmol/h per milligram of protein) in this 
patient. Unfortunately, EMG, CT, MRI, or urinary sul-
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412
follicle determination were not performed in this patient, 
and the patient is unavailable for further studies. That 
this patient has an as yet unobserved MLD mutation in 
his ASA gene in addition to the PD mutation cannot be 
excluded.
An overlap exists between the ASA activity levels of 
patients with MLD (1 to 12 nmol/h per milligram of pro­
tein) and patients with PD ( 6  to 25 nmol/h per milli­
gram of protein) (Figure 1), confirming that determina­
tion of ASA activity level is not sufficient for differentiation 
between MLD and PD, In patients aged 17 to 40 years 
with progressive symptoms of mental deterioration, be­
havioral abnormalities, or ataxia, in combination with 
hypomyelination of the central nervous system and slow­
ing of NCVs, a diagnosis of MLD should be considered. 
Diagnosis of adult MLD can be confirmed by determi­
nation of ASA activity in leukocytes or fibroblasts and 
accumulation of sulfaticles in different tissues or urine, 
and PD should be confirmed or excluded by means of 
DNA analysis.
Accepted fo r  publication April 5, 1994,
Reprint requests to the Department o f Neurology, Uni­
versity Hospital Nijmegen , PO Box 9101 , 6500 IiB N i­
jmegen, the Netherlands (Dr Gabreels).
1. Kolodny EH. Metachromatic leukodystrophy and multiple sulfatase deficiency. 
In: Scrlver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic Basis of in­
herited Disease, 6th ed, New York, NY: McGraw-Hill International Book Co; 
1989.
2. MacFaul R, Cavanagh N, Lake BD, Stephens R, Whitfield AE. Metachromatic 
leukodystrophy: review of 38 cases. Arch Dis Child. 1982;57:168-175.
3. Haltla T, Jorma P, Haltla M, Icen A. Juvenile metachromatic leukodystrophy: 
clinical, biochemical and neuropatholeglc studies In nine new cases. Arch Neu­
rol, 1980;37:42-46.
4. Baumann N, Masson M, Carreau V, Lefevro M, Horschkowltz N, Turpin JC. 
Adult forms of metachromatic leukodystrophy: clinical and biochemical ap­
proach. Dev Neuroscl. 1991;13:211-215.
5. Sadeh M, Kurltzky A, Ben-Davld E, Goldhammer Y. Adult metachromatic leu­
kodystrophy with an unusual relapsing-remltting course. Postgrad Med J. 1992; 
68:192-195.
6. Fressinaud C( Vallat J, Masson M, Jauberteau MO, Baumann N, Hugon J. Adult- 
onset metachromatic leukodystrophy presenting as Isolated peripheral neu­
ropathy. Neurology, 1992;42:1396-1398.
7. Gleselmann V, Polten A, Kreyslng J, von Figura K. Arylsulfatase A psoudode- 
ilclency: loss of a polyadenylatlon signal and N-glycosylatlon sito. Proc Natl 
Acad Scl USA,  1989;86:9436-9440,
8. Hohonschutz C, Elch P, Frledl W, Walieed A, Conzolmann E, Propping P. Pseu- 
dodeflclency of arylsulfatase A: a common genetic polymorphism with pos­
sible disease implications. Hum Genet. 1989;82:45-48.
9. Gleselmann V, Polten A, Kreyslng J, et al. Mutations in arylsulfatase A allolos 
causing metachromatic leukodystrophy. Brain DysfuncL 1991;4:235-243.
10. Hoes MJAJM, Lamers KJ, Homines OR, tor Haar B. Adult metachromatic leu­
kodystrophy: arylsulphatase-A values In four generations of one family and 
some reflections about the genetics. Ctin Neurol Neurosurg. 1977:80:174- 
188.
11. Galjaard H. Genetic Metabolic Diseases: Early Diagnosis and Prenatal Analy­
sis. Amsterdam, the Netherlands: Elsevier Science Publishers; 1980:823-824,
12. Gleselmann V. An assay for the rapid detection of the arylsulfatase A pseu- 
dodeflciency allele facilitates diagnosis and genetic counseling for metachro­
matic leukodystrophy. Hum Genet. 1991;86:251-255.
13. Nelson PV, Carey WF, Morris CP. Population frequency of the arylsulfatase A 
pseudodeficiency allele. Hum Genet 1991;87:87-88.
14. Bosch EP, Hart MN. Late adult-onset metachromatic leukodystrophy: demen­
tia and polyneuropathy In a 63-year-old man. Arch Neurol, 1978;35:475-477.
15. Tagliavlnl F, Pletrlnl V, Plllerl G, Trabattonl G, Lechi A. Adult metachromatic 
leukodystrophy: clinlcopathologlcal report of two familial cases with slow courso. 
Neuropathol Appl Neuroblol. 1979;5:233-243.
16. Hydo TM, Zleglor JC, Weinberger DR. Psychiatric disturbances In metachro­
matic leukodystrophy. Arch Neurol. 1992;49:401-406,
17. De Mulder C, Martin JJ. Leucody strop h le metachromatlque de Padulte, Acta 
Neurol Belg. 1987;78:162-166,
18. Skomer C, Stears J, Austin J, Metachromatic leukodystrophy (MLD), XV: adult 
MLD wltli focal lesions by computed tomography. Arch Neurol. 1983;40:354- 
355.
19. Flnelll PF. Metachromatic leukodystrophy manifesting as a schizophrenic dis­
order: computed tomographic correlation. Ann Neurol. 1985;18:94-95.
20. Relder-Grosswasser I, Bornsteln N. CT and MRI In late-onsot metachromatic 
leukodystrophy. / t o  Neurol Scand. 1987:75:64-69.
21. Brlon S, Mikoi J, Graveleau J. Leucodystrophie metachromatique de l'adulte 
jeune: étude clinique, biologique et uitrastructurale. Rev Neurol. 1970:122: 
161-176.
22. Percy AK, Kaback MM, Herndon RM. Metachromatic leukodystrophy: com­
parison of early and late-onset forms. Neurology. 1977:27:933-941.
23. Thomas PKt King RHM, Kocen RS, Brett EM. Comparative ultrastructural ob­
servations on peripheral nerve abnormalities in the late infantile, juvenile and 
late onset forms of metachromatic leucodystrophy. Acta Neuropathol Berl. 1977: 
39:237-245.
24. Alves D, Pires MM, Guimaraes A, Miranda MC. Four cases of late onset meta- 
chromatic leucodystrophy in a family: clinical, biochemical and neuropatho- 
loglcal studies. J Neurol Neurosurg Psychiatry. 1986;49:1417-1422.
25. Bardosl A, Frlede RL, Ropte S, Goobel HH. A morphomotrlc study on sural 
nerves in motachromatic leucodystrophy. Brain, 1987;110:683-694.
26. Martin JJ, Ceutorlck C, Morcelis R, Jorls C. Pathology of porlphoral norvos In 
metachromatic leucodystrophy: a comparative study of ten cases. J Neurol 
Scl. 1982:53:95-112.
27. Bayever E, Phlllppart M, Nuwer M, et al. Bono-marrow transplantation for meta­
chromatic leucodystrophy. Lancet. 1985;2:471-473.
28. Krivit W, Shapiro E, Kennedy W, ot al. Treatment of late Infantile metachro­
matic leukodystrophy by bone marrow transplantation. N Engl J Med. 1990: 
322:28-32.
29. Kappler J, Potter W, Gloselmann V, Klossllng W, Frledl W, Propping P. Pho- 
notyplc conséquences of low arylsulfatase A genotypes (ASAp/ASAp and ASA / 
ASAp): does there oxlst an association with multiple sclerosis? DevNourosci 
1991;13:228-231.
30. Sanglorl S, Monchl M, Capellarl S, Plotrobollo MV, Marcltello I, Montagna P. 
Movement disorders In arylsulfatase A psoudodoflcloncy (ASAPD). Neurology 
1992;42(suppl 3}:155.
Conversion From Syst&me International (SI) Units to Traditional Units (Modified From The SI Manual In Health Care)
SI Conversion Traditional 
Reference SI Factor Reference Traditional 
System Component Interval* Unit (Divide by) interval“' Unit
Cerebrospinal
fluid Protein, total <0.40 g/L 0.01 < 4 0  mg/dL
* These reference values are not intended to bo definitive since each laboratory determines its own values. They are provided (or illustration only.
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